Unlike most of her Senate colleagues involved in the stock market, Minnesota's Tina Smith maintains a unique portfolio.
Insulet (NASDAQ:PODD – Get Free Report) had its target price increased by investment analysts at TD Cowen from $264.00 to ...
Intuitive Surgical (ISRG), and Insulet (PODD) stocks were cited as top MedTech stock picks for 2025 by J.P. Morgan. Read more ...
Shares of Insulet Corp. PODD rose 3.68% to $266.30 Friday, on what proved to be an all-around favorable trading session for ...
Buying $100 In PODD: If an investor had bought $100 of PODD stock 10 years ago, it would be worth $598.02 today based on a ...
TD Cowen raised the firm’s price target on Insulet (PODD) to $324 from $264 and keeps a Buy rating on the shares. The firm thinks Insulet will ...
In a report released yesterday, Josh Jennings from TD Cowen maintained a Buy rating on Insulet (PODD – Research Report), with a price target of ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
BTIG raised the firm’s price target on Insulet (PODD) to $300 from $270 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models in select Medical Technology ...
From public campaigns featuring Cyndi Lauper to ads with dinosaurs, MM+M compiles the best public marketing campaigns from ...
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An ...
Insulet develops, manufactures, and markets the Omnipod Insulin Management System for those with Type 2 diabetes. The system ...